Samsung Bioepis Holds 10th Anniversary Celebration Event

President Koh Han-seung of Samsung Bioepis (fourth from the left) and other Samsung Bioepis executives and employees are holding a commemorative tree-planting ceremony in the garden of the Incheon Songdo headquarters on the 28th to celebrate the 10th anniversary of the company's founding.

[Asia Economy Reporter Chunhee Lee] Samsung Bioepis held a founding anniversary event to prepare for a new leap forward as it celebrates its 10th anniversary.

Samsung Bioepis announced on the 28th that it held a founding anniversary event to mark its 10th anniversary. The event, conducted both online and offline, looked back on the past 10 years, included an awards ceremony recognizing outstanding employees and partner companies, and featured a commemorative tree planting ceremony for the 10th anniversary.

Go Han-seung, President of Samsung Bioepis, said in his founding anniversary speech, “I am proud of the achievements we have accomplished together with all employees over the past 10 years,” adding, “As we prepare for the next 10 years, let us further strengthen our expertise and continue to grow sustainably through constant change and innovation.”

Since its establishment in 2012, Samsung Bioepis has focused on the biosimilar (biopharmaceutical generic) business. Since its founding, Samsung Bioepis has obtained marketing approval for a total of six biosimilars for autoimmune disease treatments, anticancer drugs, and ophthalmic disease treatments. Among these, five products are currently being sold in global markets including Korea and Europe.

In particular, the three autoimmune disease treatment biosimilars (SB2, SB4, SB5) held by Samsung Bioepis have been cumulatively prescribed to more than 240,000 patients in Europe alone. Notably, SB4 (Enbrel biosimilar, European product name 'Benepali') ranks first in sales in the European market for that active ingredient, surpassing the original product.

Along with stable product sales performance, Samsung Bioepis is expanding research and development into ophthalmic diseases, endocrine diseases, and hematologic diseases to establish a foundation for sustainable growth.

This content was produced with the assistance of AI translation services.